Quick Answer
Lineage Cell Therapeutics, Inc. reported Research And Development Expense of $17.73 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +42.2% in Research And Development Expense from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$1.43 million | Q3 2010: -$1.81 million | Q1 2011: $2.95 million | Q2 2011: $3.33 million | Q3 2011: $3.49 million | Q1 2012: $4.18 million | Q2 2012: $4.62 million | Q3 2012: $4.55 million | Q1 2013: $5.40 million | Q2 2013: $5.53 million | Q3 2013: $6.44 million | Q1 2014: $8.41 million | Q2 2014: $9.08 million | Q3 2014: $8.84 million | Q1 2015: $9.32 million | Q2 2015: $9.06 million | Q3 2015: $11.43 million | Q1 2016: $13.73 million | Q2 2016: $8.94 million | Q3 2016: $6.42 million | Q1 2017: $6.49 million | Q2 2017: $6.27 million | Q3 2017: $6.56 million | Q1 2018: $5.94 million | Q2 2018: $6.36 million | Q3 2018: $4.88 million | Q1 2019: $4.96 million | Q2 2019: $5.24 million | Q3 2019: $4.27 million | Q1 2020: $3.34 million | Q2 2020: $2.81 million | Q3 2020: $3.57 million | Q1 2021: $3.39 million | Q2 2021: $2.93 million | Q3 2021: $2.81 million | Q1 2022: $2.99 million | Q2 2022: $3.30 million | Q3 2022: $3.59 million | Q1 2023: $4.19 million | Q2 2023: $3.87 million | Q3 2023: $3.74 million | Q1 2024: $3.01 million | Q2 2024: $2.87 million | Q3 2024: $3.17 million | Q1 2025: $3.11 million | Q2 2025: $3.11 million | Q3 2025: $3.27 million.
- Over the full 17 years of available data (2009 to 2025), Lineage Cell Therapeutics, Inc.'s Research And Development Expense has grown by 657.2%.
- Historical annual values: Fiscal year 2025: $17.73 million | Fiscal year 2024: $12.47 million | Fiscal year 2023: $15.71 million | Fiscal year 2022: $13.99 million | Fiscal year 2021: $33.91 million | Fiscal year 2020: $12.32 million | Fiscal year 2019: $17.95 million | Fiscal year 2018: $20.96 million | Fiscal year 2017: $24.02 million | Fiscal year 2016: $36.11 million | Fiscal year 2015: $42.60 million | Fiscal year 2014: $37.53 million | Fiscal year 2013: $26.61 million | Fiscal year 2012: $18.12 million | Fiscal year 2011: $13.70 million | Fiscal year 2010: $8.19 million | Fiscal year 2009: -$3.18 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: